跳到正文
Nature 干细胞主题·· 15 小时前AI 评分22

接受异基因造血干细胞移植的急性髓系白血病患者中CEBPA突变的预后影响

The prognostic impact of CEBPA mutation in acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation

AI 导读

现有证据围绕CEBPA突变在急性髓系白血病中的预后价值展开，涉及bZIP与TAD不同突变类型对结局的差异影响，以及双突变患者接受异基因造血干细胞移植的生存获益问题。相关研究提示，CEBPA双突变通常预后较好，但异基因移植能否带来额外生存获益尚存争议，不同突变亚型的预后意义仍需进一步明确。

正文

References

  1. Li M, Li Y, Qu Q, Wang C, Chen Q, Zhu X, et al. Clinical features and prognostic nomogram for therapy-related acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation. Cancer Lett. 2025;612:217460.

    Article  CAS  PubMed  Google Scholar 

  2. Taube F, Georgi JA, Kramer M, Stasik S, Middeke JM, Röllig C, et al. CEBPA mutations in 4708 patients with acute myeloid leukemia: differential impact of bZIP and TAD mutations on outcome. Blood. 2022;139:87–103.

  3. Fröhling S, Schlenk RF, Stolze I, Bihlmayr J, Benner A, Kreitmeier S, et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol. 2004;22:624–33.

    Article  PubMed  Google Scholar 

  4. Patel JP, Gönen M, Figueroa ME, Fernandez H, Sun Z, Racevskis J, et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med. 2012;366:1079–89.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Pabst T, Mueller BU, Zhang P, Radomska HS, Narravula S, Schnittger S, et al. Dominant-negative mutations of CEBPA, encoding CCAAT/enhancer binding protein-alpha (C/EBPalpha), in acute myeloid leukemia. Nat Genet. 2001;27:263–70.

    Article  CAS  PubMed  Google Scholar 

  6. Leroy H, Roumier C, Huyghe P, Biggio V, Fenaux P, Preudhomme C. CEBPA point mutations in hematological malignancies. Leukemia. 2005;19:329–34.

    Article  CAS  PubMed  Google Scholar 

  7. Zhang DE, Zhang P, Wang ND, Hetherington CJ, Darlington GJ, Tenen DG. Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice. Proc Natl Acad Sci USA. 1997;94:569–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Reddy VA, Iwama A, Iotzova G, Schulz M, Elsasser A, Vangala RK, et al. Granulocyte inducer C/EBPalpha inactivates the myeloid master regulator PU.1: possible role in lineage commitment decisions. Blood. 2002;100:483–90.

    Article  CAS  PubMed  Google Scholar 

  9. Keeshan K, Santilli G, Corradini F, Perrotti D, Calabretta B. Transcription activation function of C/EBPalpha is required for induction of granulocytic differentiation. Blood. 2003;102:1267–75.

    Article  CAS  PubMed  Google Scholar 

  10. Ahn J-S, Kim J-Y, Kim H-J, Kim Y-K, Lee S-S, Jung S-H, et al. Normal karyotype acute myeloid leukemia patients with CEBPA double mutation have a favorable prognosis but no survival benefit from allogeneic stem cell transplant. Ann Hematol. 2015;95:301–10.

    Article  PubMed  Google Scholar 

  11. Wakita S, Sakaguchi M, Oh I, Kako S, Toya T, Najima Y, et al. Prognostic impact of CEBPA bZIP domain mutation in acute myeloid leukemia. Blood Adv. 2022;6:238–47.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022;140:1345–77.

    Article  PubMed  Google Scholar 

  13. Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka H-M, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200–28.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. El-Sharkawi D, Sproul D, Allen CG, Feber A, Wright M, Hills RK, et al. Variable outcome and methylation status according to CEBPA mutant type in double-mutated acute myeloid leukemia patients and the possible implications for treatment. Haematologica. 2017;103:91–100.

  15. Schlenk RF, Taskesen E, van Norden Y, Krauter J, Ganser A, Bullinger L, et al. The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPA. Blood. 2013;122:1576–82.

    Article  CAS  PubMed  Google Scholar 

  16. Tien F-M, Hou H-A. CEBPA mutations in acute myeloid leukemia: implications in risk stratification and treatment. Int J Hematol. 2024;120:541–7.

    Article  PubMed  Google Scholar 

  17. Kumar RD, Searleman AC, Swamidass SJ, Griffith OL, Bose R. Statistically identifying tumor suppressors and oncogenes from pan-cancer genome-sequencing data. Bioinformatics. 2015;31:3561–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022;36:1703–19.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Zhang X-H, Chen J, Han M-Z, Huang H, Jiang E-L, Jiang M, et al. The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update. J Hematol Oncol. 2021;14:145.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2016;129:424–47.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Wouters BJ, Louwers I, Valk PJM, Löwenberg B, Delwel R. A recurrent in-frame insertion in a CEBPA transactivation domain is a polymorphism rather than a mutation that does not affect gene expression profiling-based clustering of AML. Blood. 2007;109:389–90.

    Article  CAS  PubMed  Google Scholar 

  22. Mannelli F, Piccini M, Frigeni M, Gianfaldoni G, Bencini S, Salmoiraghi S, et al. Impact of baseline genetic profile and treatment on outcome and hematological toxicity in CEBPA-mutated AML. Blood Cancer J. 2025;15:27.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Pabst T, Eyholzer M, Haefliger S, Schardt J, Mueller BU. Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia. J Clin Oncol. 2008;26:5088–93.

    Article  CAS  PubMed  Google Scholar 

  24. Georgi J-A, Stasik S, Kramer M, Meggendorfer M, Röllig C, Haferlach T, et al. Prognostic impact of CEBPA mutational subgroups in adult AML. Leukemia. 2024;38:281–90.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Ahn S-Y, Kim T, Kim M, Song G-Y, Jung S-H, Yang D-H, et al. Clinical significance of bZIP in-frame CEBPA-mutated normal karyotype acute myeloid leukemia. Cancer Res Treat. 2023;55:1011–22.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Wu L-X, Liao M-Y, Zhao M-Y, Yan N, Zhang P, Liu L-X, et al. Prognostic value of CEBPA bZIP signatures in cytogenetically normal acute myeloid leukaemia. Br J Haematol. 2025;208:170–8.

  27. Schmidt L, Heyes E, Scheiblecker L, Eder T, Volpe G, Frampton J, et al. CEBPA-mutated leukemia is sensitive to genetic and pharmacological targeting of the MLL1 complex. Leukemia. 2019;33:1608–19.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Heyes E, Wilhelmson AS, Wenzel A, Manhart G, Eder T, Schuster MB, et al. TET2 lesions enhance the aggressiveness of CEBPA-mutant acute myeloid leukemia by rebalancing GATA2 expression. Nat Commun. 2023;14:6185.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Rampal R, Alkalin A, Madzo J, Vasanthakumar A, Pronier E, Patel J, et al. DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia. Cell Rep. 2014;9:1841–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Radomska HS, Alberich-Jordà M, Will B, Gonzalez D, Delwel R, Tenen DG. Targeting CDK1 promotes FLT3-activated acute myeloid leukemia differentiation through C/EBPα. J Clin Invest. 2012;122:2955–66.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Alachkar H, Mutonga M, Malnassy G, Park J-H, Fulton N, Woods A, et al. T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia. Oncotarget. 2015;6:33410–25.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Wang H, Li X-Q, Chu T-T, Han S-Y, Qi J-Q, Tang Y-Q, et al. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation. J Cancer Res Clin Oncol. 2021;147:2659–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Levis MJ, Hamadani M, Logan BR, Jones RJ, Singh AK, Litzow MR, et al. Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML. Blood. 2025;145:2138–48.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Xuan L, Wang Y, Huang F, Fan Z, Xu Y, Sun J, et al. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial. Lancet Oncol. 2020;21:1201–12.

    Article  CAS  PubMed  Google Scholar 

Download references

来源：Nature 干细胞主题 · nature.com

临床转化#临床转化#临床结果